Biomarker Discovery

The development of the biomarkers for translational medicine is a multistep process, and Exonn's experts can assist you in each step of this process:

Step 1: Experimental Design

This is a critical step that is often overlooked by researchers. Proper experimental design is essential to successful biomarker discovery and validation. For instance, the sample size for each group must be large enough to ensure adequate statistical significance. If the sample size is too low, more biomarker candidates may be unfruitful in the validation phase (false positives), and some useful biomarker candidate may be missed (false negatives). Our Biostatistic and Bioinformatics Group can assist you in determining a minimal sample size for statistical significance.

Consideration of experimental methods is another significant aspect of biomarker development. Careful definition of patient populations (or animals in the case of experimental model systems), choosing an suitable sample type, and standardized sample handling and storage protocols can make the change between success and failure in biomarker development studies. While our Technical Support personnel and scientists cannot be experts in every field of study, we can support you in reviewing experimental methods for optimal use with antibody array products.

Step 2: Candidate Screening

Exonn has developed an innovative platform for biomarker discovery and validation. The cost, specialized equipment and training required for biomarker discovery using mass spectrometry and 2-D gel electrophoresis is prohibitive to most researchers. Our approach is much faster than with traditional proteomic methods and at a fraction of the cost. Additionally, the antibodies used in our screening arrays are in most cases identical to those in our multiplex quantitative arrays and single target ELISA kits. This streamlines the workflow for biomarker development, making it faster and more affordable.

Step 3: Candidate Validation

Modest budgets can screen for hundreds of potential cytokine biomarker candidates to find the most promising ones for further investigation, much faster than with traditional proteomic methods and at a fraction of the cost. Additionally, the antibodies used in our screening arrays are in most cases identical to those in our multiplex quantitative arrays and single target ELISA kits. This streamlines the workflow for

Step 4: Clinical Applications

While Exonn's reagents and immuoassays are intended for research use only, we are fully willing and capable to validate one or more of our immunoassays or array platforms for the development of clinical assays. Exonn can offer its technical expertise as well as assistance in preparing and submitting data for clinical assay approval.

Data Statistics

We apply comprehensive statistical and data mining analysis to discover potential biomarker panels and meaningful patterns. Biostatistical analysis helps to evaluate the quality of protein expression data by detecting and extracting errors and confidence level.